Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Update: Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
This update from the Pediatric Pandemic Network (PPN) describes the new guidelines from the CDC with additional recommendations from the FDA, AAP, and AAFP. There …
Ask aRCie
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
2024
· Children's National Hospital
This study looks at how respiratory syncytial virus (RSV) affects children in the ICU. It describes that 11.4% of pediatric ICU admissions are due to …
Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines
2024
· Children's National Hospital,
· University of South Florida,
· University of Alabama at Birmingham,
· University of Colorado,
· University of Cincinnati
This article summarizes updates from the Advisory Committee on Immunization Practices (ACIP), a group advising the CDC, relevant to pediatrics, including recommendations for COVID-19 and …
Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol
2024
· Instituto de Investigación Sanitaria,
· World Health Organization (WHO),
· University of Santiago de Compostela,
· Instituto de Salud Carlos III
The NIRSE-GAL study in Galicia, Spain, aims to assess the effectiveness of nirsevimab in preventing hospitalizations due to Respiratory Syncytial Virus (RSV) in infants. It …
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluated the cost-effectiveness of using nirsevimab to prevent respiratory syncytial virus (RSV) in infants and high-risk children. By analyzing healthcare data, it was …
Nirsevimab Coverage, Children 0 to 7 months, United States
The report describes how nirsevimab coverage for infants 0 to 7 months is tracked in the U.S. using data from Immunization Information Systems (IIS). It …
Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024
2024
· New York City Department of Health and Mental Hygiene,
· Centers for Disease Control and Prevention (CDC)
This analysis reviewed nirsevimab dosing based on Vaccines for Children (VFC) eligibility in New York City during the 2023–24 RSV season. A nirsevimab shortage in …
Indian Health Service Nirsevimab Vaccine Update
2024
· Indian Health Service
This document provides information on nirsevimab and recommendations for its use, including an administration visual guide. It addresses the documentation of administered doses and reconciliation …
Nirsevimab Administration Visual Guide
This 2-page infographic includes a flowchart to aid in making decisions about nirsivemab administration and dosing in infants and toddlers. It provides immunization administration tips, …
Drug Trials Snapshots: BEYFORTUS
This webpage features a drug trial snapshot for the drug Beyfortus, a monoclonal antibody given as an injection to protect against RSV. Snapshots reveal participants …